ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2465

Seroresponse Rates After Influenza Vaccination in Rheumatoid Arthritis Patients Treated with Biological Agents During the 2011–2012 Flu Season

Masatoshi Hayashi1, Toshihisa Kojima2, Naoki Ishiguro3, Tomonori Kobayakawa4 and Toshihisa Kanamono1, 1Departments of Orthopedic surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, 2Orthopedic Surgery and Rheumatology, Nagoya Univeristy, School of Medicine, Nagoya, Japan, 3Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, 4Orthopedic Surgery, Nagoya university, Nagoya, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Abatacept, etanercept, rheumatoid arthritis (RA) and vaccines

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research IV: Outcomes and Costs in Rheumatic Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: At present, annual vaccination against influenza is recommended for rheumatoid arthritis (RA) patients. However, whether humoral responses to influenza vaccine are impaired in RA patients treated with biological agents remains controversial. This study aimed to compare seroresponse rates after influenza vaccination in RA patients treated with five biological agents.

Methods: Trivalent influenza subunit vaccines containing A/H1N1, A/H3N2, and B-1 were administered subcutaneously once to 64 RA patients treated with methotrexate (MTX, control, n = 15), infliximab (IFX, n = 12), etanercept (ETN, n = 11), adalimumab (ADA, n = 3), tocilizumab (TCZ, n = 12), or abatacept (ABT, n = 11). We measured antibody titers using hemagglutination inhibition (HI) test at baseline and 4–8 weeks after vaccination. The immunogenicity end points were the proportion of patients with antibody titers of 1:40 or more on HT test and the proportion of patients with either seroconversion or a significant increase in antibody titer.

Results: Table 1 shows baseline characteristics of all the 64 RA patients. Seroconversion and seropositive rates (%) after subcutaneous vaccination were 54.3 and 64.4, respectively, in MTX; 46.2 and 61.1, respectively, in IFX; 73.3 and 87.9, respectively, in ETN; 62.5 and 66.7, respectively, in ADA; 48.3 and 58.3, respectively, in TCZ; and 21.4 and 33.3, respectively, in ABT. Seronegative rates (%) were 45.7 in MTX, 53.8 in IFX, 26.7 in ETN, 37.5 in ADA, 51.7 in TCZ, and 78.6 in ABT (Table 2). Both the decrease in the seroresponse rate after influenza vaccination in the ABT group and increase in the seropositive rate in the ETN group were significant compared with those in the MTX control group (P < 0.01) (Table 2). Of the 64 RA patients, only one patient in the MTX group was infected by influenza during this season.

Conclusion: RA patients treated with ABT exhibited compromised immune responses to influenza vaccine compared with those treated with MTX or other biological agents. Therefore, RA patients treated with ABT would benefit from repeated influenza vaccinations.

Table 1. Baseline characteristics of 64 RA patients

Agents

Number of patients

Males (%)

Mean age ± SD (years)

PSL rate (%)

Mean usage of PSL ± SD (mg/day)

MTX

15

6.7

68.3 ± 9.8

33.3

4.1 ± 2.2

IFX

12

16.7

61.6 ± 10.8

66.7

3.9 ± 2.1

ETN

11

9.1

58.6 ± 15.6

54.5

3.5 ± 2.4

ADA

3

33.3

69.3 ± 7.0

33.3

5.0 ± 0.0

TCZ

12

25.0

67.7 ± 12.8

58.3

3.6 ± 1.7

ABT

11

27.3

62.0 ± 9.8

81.8

3.8 ± 2.8

RA, rheumatoid arthritis; SD, standard deviation; PSL, prednisolone; MTX, methotrexate; IFX, infliximab; ETN, etanercept; ADA, adalimumab; TCZ, tocilizumab; ABT, abatacept

Table 2. Seroresponse rates to influenza vaccination in 64 RA patients treated with MTX or five biological agents (192 vaccines)

Agents

Number of vaccinations

Seroconversion (%)

Seropositive (%)

Seronegative (%)

MTX

45

54.3

64.4

45.7

IFX

36

46.2

61.1

53.8

ETN

33

73.3

87.9**

26.7

ADA

9

62.5

66.7

37.5

TCZ

36

48.3

58.3

51.7

ABT

33

21.4**

33.3**

78.6**

**significant difference from MTX (control). **: P < 0.01.

RA, rheumatoid arthritis; MTX, methotrexate; IFX, infliximab; ETN, etanercept; ADA, adalimumab; TCZ, tocilizumab; ABT, abatacept


Disclosure:

M. Hayashi,
None;

T. Kojima,
None;

N. Ishiguro,

Abbott Japan, Chugai Pharmaceutical Co., Ltd., Daiichi-Sankyo Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma, Pfizer Japan Inc., and Takeda Pharmaceutical Co., Ltd.,

2,

Abbott Japan, Chugai Pharmaceutical Co., Ltd., Daiichi-Sankyo Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma, Pfizer Japan Inc., and Takeda Pharmaceutical Co., Ltd.,

8;

T. Kobayakawa,
None;

T. Kanamono,

Santen Pharmaceutical,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/seroresponse-rates-after-influenza-vaccination-in-rheumatoid-arthritis-patients-treated-with-biological-agents-during-the-2011-2012-flu-season/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology